ICON Announces Agreement with Intel Allowing Integration of the Intel® Pharma Analytics Platform for Clinical Trials
17 Avril 2018 - 1:28PM
Business Wire
ICON plc, (NASDAQ: ICLR) a global provider of drug development
solutions and services to the pharmaceutical, biotechnology and
medical device industries, today announced that it has agreed on
preliminary deal terms with Intel Corporation to enable ICON to
offer the Intel® Pharma Analytics Platform for use in clinical
trials. The Intel platform is an edge-to-cloud artificial
intelligence (AI) solution that enables remote monitoring and
continuous capture of clinical data from study subjects using
sensors and wearable devices, and can apply machine learning
techniques to objectively measure symptoms and quantify the impact
of therapies.
Jointly configured by ICON experts and building on Intel’s AI
and analytics leadership, trials that leverage the Intel® Pharma
Analytics Platform can:
- Capture de-identified, objective,
high-quality, rich sensory data via sensors and wearable
devices.
- Get real-time information about
protocol adherence while helping patients manage medication,
perform structured tests and report symptoms.
- Utilize smartphone applications to
collect electronic diaries and patient reported outcomes
(PROs).
- Transmit the de-identified data to a
secured cloud infrastructure for storage and analysis.
- Apply machine learning and other AI
methods to objectively assess and quantify the severity of
symptoms, quantify the impact of therapies such as medication
efficacy or dose response.
The Intel® Pharma Analytics Platform provides benefits for
pharmaceutical companies seeking to speed and simplify clinical
trials, reduce trial costs, and gather more objective evidence; by
transitioning to automatic collection of consistent, unbiased data,
remote monitoring for data analysis, and delivering improved
patient experience. These changes will help accelerate
time-to-market for new drugs, by producing high-quality data and
increasing patient retention, leading to shorter trials.
Intel values individuals’ privacy and employs technical and
organizational measures where appropriate to protect the privacy
and security of the personal data of the users of the Intel® Pharma
Analytics Platform, as required by Articles 28 and 32 GDPR and any
other applicable laws. Where appropriate, Intel performs data
protection impact assessments as required under Article 35
GDPR.
“Our engagement with Intel confirms ICON’s position as the
leading CRO for advancing the use of wearable technology, and will
expand ICON’s existing offering to include a service where data can
be aggregated and analysed from mhealth and wearable technologies,
with advanced analytics allowing for development of novel endpoints
and digital biomarkers,” commented Steve Cutler, CEO at ICON.
“Furthermore, the platform supports patient centric trial designs
by reducing or eliminating the need for patients to travel to
sites, and can be integrated with our Direct to Patient Call Centre
(DPC) providing a seamless compliance monitoring service.”
“Intel is accelerating the pace of digital transformation, and
IT plays a leading role in delivering solutions on that journey,”
says Paula Tolliver, Corporate Vice President and Chief Information
Officer, Intel Corporation. “With the power of AI, the Intel®
Pharma Analytics Platform helps the clinical trial industry reduce
costs and deliver fresh insights for drug development, potentially
saving thousands of lives.”
About ICON plc ICON plc is a global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries. The company
specialises in the strategic development, management and analysis
of programs that support clinical development - from compound
selection to Phase I-IV clinical studies. With headquarters in
Dublin, Ireland, ICON currently, operates from 97 locations in 38
countries and has approximately 13,250 employees. More information
is at http://www.iconplc.com/wearables
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417005896/en/
For ICONWeber ShandwickOlivia Pimenta+44 (0)207
067 0557OPimenta@webershandwick.com
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024